Latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus interacts with Tat and activates the long terminal repeat of human immunodeficiency virus type 1 in human cells

Journal of Virology

Volumn 75, Issue 18, 2001, Pages 8761-8771

  Hyun, T S ^a   Subramanian, C ^a   Cotter II, M A ^a   Thomas, R A ^a   Robertson, E S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LATENCY ASSOCIATED NUCLEAR ANTIGEN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL STRAIN U937; CONTROLLED STUDY; HERPES VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; KAPOSI SARCOMA; LONG TERMINAL REPEAT; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; UNITED STATES;

ANTIGENS, VIRAL; CELL LINE; CELL LINE, TRANSFORMED; CELL NUCLEUS; GENE PRODUCTS, TAT; HERPESVIRUS 8, HUMAN; HIV CORE PROTEIN P24; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; NUCLEAR PROTEINS; TRANS-ACTIVATION (GENETICS); TRANSFECTION; U937 CELLS; VIRUS LATENCY;

EID: 0034881511     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.18.8761-8771.2001     Document Type: Article

References (52)

1. Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus
2. Oncogenic forms of NOTCH1 lacking either the primary binding site for RBP-Jkappa or nuclear localization sequences retain the ability to associate with RBP-Jkappa and activate transcription
3. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mediates episome persistence through cis-acting terminal repeat (TR) sequence and specifically binds TR DNA
4. The epidemiology of cancer in AIDS patients
5. Epidemiology of Kaposi's sarcoma
6. Sexual spread of Kaposi's
7. Trans activation of human immunodeficiency virus type 1 is sequence specific for both the single-stranded bulge and loop of the trans-acting-responsive hairpin: A quantitative analysis
8. Tat trans-activates the human immunodeficiency virus through a nascent RNA target
9. The epidemiology of AIDS-related neoplasms
10. Monocytes in Kaposi's sarcoma lesions are productively infected by human herpesvirus 8
11. Distinct patterns of viral antigen expression in Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus coinfected body-cavity-based lymphoma cell lines: Potential switches in latent gene expression due to coinfection
12. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas
13. Kaposi's sarcoma-associated herpesvirus: A lymphotropic human herpesvirus associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease
14. Kaposi's sarcoma-associated herpesvirus in non-AIDS related lymphomas occurring in body cavities
15. The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells
16. Modulation of histone acetyltransferase activity through interaction of Epstein-Barr nuclear antigen 3C with prothymosin alpha
17. Spontaneous activation of the lytic cycle in cells infected with a recombinant Kaposi's sarcoma-associated virus
18. Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro
19. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation
20. Propagation of a human herpesvirus from AIDS-associated Kaposi's sarcoma
21. p53 inhibition by the LANA protein of KSHV protects against cell death
22. Production of HIV-1 by human B cells infected in vitro: Characterization of an EBV genome-negative B cell line chronically synthetizing a low level of HIV-1 after infection
23. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma
24. Efficient synthesis of viral nucleic acids following monocyte infection by HIV-1
25. Interaction of human immunodeficiency virus type 1 Tat with the transcriptional coactivators p300 and CREB binding protein
26. Classic Kaposi sarcoma: Epidemiology and risk factors
27. Classic Kaposi's sarcoma as a second primary neoplasm
28. Seroprevalence of Kaposi's sarcoma-associated herpesvirus in healthy adults in Israel
29. Activation of the AIDS retrovirus promoter by the cellular transcription factor, Sp1
30. Identification of the gene encoding the major latency-associated nuclear antigen of the Kaposi's sarcoma-associated herpesvirus
31. The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): Distribution of infection in KS risk groups and evidence for sexual transmission
32. Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL cells
33. Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: Evidence for limited defectiveness and complementation
34. Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: Identification of replication-competent and -defective viral genomes
35. Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) binds ATF4/CREB2 and inhibits its transcriptional activation activity
36. Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma
37. A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter
38. An interaction between the DNA-binding domains of RelA(p65) and Sp1 mediates human immunodeficiency virus gene activation
39. A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation
40. Close but distinct regions of human herpesvirus 8 latency-associated nuclear antigen 1 are responsible for nuclear targeting and binding to human mitotic chromosomes
41. Latent nuclear antigen of Kaposi's sarcoma-associated herpesvirus interacts with RING3, a homolog of the Drosophila female sterile homeotic (fsh) gene
42. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene hras transforms primary rat cells
43. Modulation of cellular and viral gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus
44. Limited transmission of Kaposi's sarcoma-associated herpesvirus in cultured cells
45. Regulation of HIV-1 transcription
46. Carboxy terminus of human herpesvirus 8 latency-associated nuclear antigen mediates dimerization, transcriptional repression, and targeting to nuclear bodies
47. Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen
48. Epstein-Barr virus nuclear protein EBNA-3C interacts with the human metastatic suppressor Nm23-mH1: A molecular link to cancer metastasis
49. HIV-1-trans-activating (Tat) protein: Both a target and a tool in therapeutic approaches
50. Basal and Tat-transactivated expression from the human immunodeficiency virus type 1 long terminal repeat in human placental trophoblast rules out promoter-enhancer activation as the partial block to viral replication
51. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma